



Epidemiology and Characteristics of Metallo- β -Lactamase-Producing *Pseudomonas aeruginosa*

Duck Jin Hong^{1*}, Il Kwon Bae^{2*}, In-Ho Jang³, Seok Hoon Jeong¹, Hyun-Kyung Kang², and Kyungwon Lee¹

¹Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul;

²Department of Dental Hygiene, Silla University, Busan; ³Department of Biomedical Laboratory Science, College of Health Sciences, Sangji University, Wonju, Korea

Metallo- β -lactamase-producing *Pseudomonas aeruginosa* (MPPA) is an important nosocomial pathogen that shows resistance to all β -lactam antibiotics except monobactams. There are various types of metallo- β -lactamases (MBLs) in carbapenem-resistant *P. aeruginosa* including Imipenemase (IMP), Verona integron-encoded metallo- β -lactamase (VIM), Sao Paulo metallo- β -lactamase (SPM), Germany imipenemase (GIM), New Delhi metallo- β -lactamase (NDM), Florence imipenemase (FIM). Each MBL gene is located on specific genetic elements including integrons, transposons, plasmids, or on the chromosome, in which they carry genes encoding determinants of resistance to carbapenems and other antibiotics, conferring multidrug resistance to *P. aeruginosa*. In addition, these genetic elements are transferable to other Gram-negative species, increasing the antimicrobial resistance rate and complicating the treatment of infected patients. Therefore, it is essential to understand the epidemiology, resistance mechanism, and molecular characteristics of MPPA for infection control and prevention of a possible global health crisis. Here, we highlight the characteristics of MPPA.

Key Words: Metallo- β -lactamase; *Pseudomonas aeruginosa*; Carbapenem; Epidemiology; Multidrug resistance

Introduction

The continuous emergence, worldwide spread, and increas-

ing prevalence of bacteria resistant to multiple antimicrobial agents are becoming major threats to public health [1-5]. Multidrug and pandrug resistant (MDR or PDR) bacterial infec-

Received: June 8, 2015

Corresponding Author : Seok Hoon Jeong, MD, PhD

Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea
Tel: +82-2-2019-3532, Fax: +82-2-2057-8926

E-mail: kscpjsh@yuhs.ac

Alternative Corresponding Author: Duck Jin Hong, MD

Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea
Tel: +82-2-2019-3777, Fax: +82-2-2057-8926

E-mail: dududuck@yuhs.ac

* These authors contributed equally to this work.

* All authors have seen and approved the manuscript and contributed significantly to the work. This review has not been previously published nor is it being considered for publication elsewhere.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyrights © 2015 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy

www.icjournal.org



Table 1. Carbapenem-resistant *Pseudomonas aeruginosa* report by country

Continent	Country ^a	Collection period (year)	Resistance rate (%)					Reference or GenBank accession No.
			Carbapenem	Imipenem	Meropenem	Doripenem	Ertapenem	
East Asia	China	2003-2011		43.4	40.9			[70]
	Japan	2013		28.5	22.8	12.5		[71]
	Korea	2011		22				[61]
	Taiwan	2003-2011		16	19			[72]
Southeast Asia	Philippines	2010	31.1					[73]
	Singapore	2010	23.3					[73]
	Thailand	2010	28.7					[73]
	Vietnam	2010	46.7					[73]
South Asia	India	2011	32					[74]
	Iran	2011-2012			31.8	13.5	74.4	[75]
North Asia	Russia	2008-2010	75.3					[37]
Southwest Asia	Israel	2009-2011				24.7		[76]
	Saudi Arabia	2009-2010		56	34			[77]
	Turkey	2009-2011				49.2		[76]
West Europe	Belgium	2009-2011				41.1		[76]
	France	2009-2011				18.2		[76]
	Germany	2009-2011				24.4		[76]
	Greece	2011				50.0		[78]
	Ireland	2009-2011				13.8		[76]
	Italy	2009-2011				19.9		[76]
	Portugal	2009-2011				35.6		[76]
	Spain	2009-2011				21.0		[76]
	Switzerland	2009-2011				21.7		[76]
North Europe	Poland	2009-2011				70.7		[76]
	Sweden	2009-2011				10.9		[76]
Oceania	Australia	2011	16					[74]
	New Zealand	2010	10.3					[73]
North Africa	Algeria	2009-2012		39.3				[79]
East Africa	Kenya	2006-2007	13.7					[80]
South Africa	South Africa	2006		45	42			[81]
North America	Canada	2009-2010	3.3					[82]
	Mexico	2005-2010		22				[83]
	US	2012-2013	20					[84]
Central America	Costa Rica	Unavailable	63.1					[85]
	Dominica Republic	2010		8	8			[86]
	El Salvador	2010		25	24			[86]
	Guatemala	2010		36	34			[86]
	Honduras	2010		20				[86]
	Nicaragua	2010		32	40			[86]
	Panama	2010		34	23			[86]
	South America	Argentina	2010		33	37		
Bolivia		2010		20	14			[86]
Brazil		2005		37-57	36-52			[86]
Chile		2005		32-40	30-33			[86]
Columbia		2010		17	19			[86]
Ecuador		2010		21	27			[86]
Paraguay		2010		30	30			[86]
Peru		2010		66	57			[86]
Uruguay		2010		35	43			[86]
Venezuela		2010		33				[86]

^aCountries are listed in alphabetical order.

tions are closely associated with high mortality, prolonged hospitalization, multiple morbidities, and increased cost due to the limited antimicrobial therapeutic options for infected patients [6, 7]. *Pseudomonas aeruginosa* is one of the primary opportunistic pathogen that causes a variety of nosocomial infections including sepsis, pneumonia, urinary tract infection, and soft-tissue infection [8]. This species is frequently isolated from immunocompromised patients who underwent organ transplantation, invasive procedure, immunosuppressive therapy, or intensive care [9-11].

P. aeruginosa is one of the most important bacteria with documented resistance to multiple antimicrobial classes including β -lactams, carbapenems, aminoglycosides, fluoroquinolones, and polymyxins [12, 13]. Due to its intrinsic and acquired antimicrobial resistance, only limited classes of antibiotics are effective for the treatment of *P. aeruginosa* infections. Among these antibiotics, carbapenems have been regarded as the most potent β -lactams against MDR Gram-negative bacilli including *P. aeruginosa* due to their high affinity with penicillin-binding proteins, stability against extended-spectrum β -lactamases (ES- β BLs), and permeability of bacterial outer membranes [14]. Resistance to carbapenems is particularly challenging in clinical settings because they are the mainstays for treatment of multidrug resistance *P. aeruginosa*. There are few remaining antibiotic options for this strain, and multidrug resistance is much

more common for patients infected with carbapenem-resistant *P. aeruginosa* [6, 15, 16].

Among the various antimicrobial resistance mechanisms, the production of carbapenemase is one of the most important mechanisms by which *P. aeruginosa* acquires carbapenem resistance. Many carbapenemases have been identified in *P. aeruginosa*, including (1) KPC and GES variants of Ambler class A, (2) IMP-, VIM-, SPM-, GIM-, NDM-, and FIM-type metallo- β -lactamases (MBLs) of Ambler class B, and (3) OXA variant enzymes of Ambler class D [17-25].

Here, we overview the epidemiology and molecular characteristics of metallo- β -lactamase-producing *P. aeruginosa* (MPPA).

Epidemiology of carbapenem-resistant *P. aeruginosa*

The global epidemiology of carbapenem-resistant *P. aeruginosa* (CRPA) was analyzed based on a careful and thorough literature search of <http://www.ncbi.nlm.nih.gov/pubmed> with the combination of key words including the name of each nation, carbapenem, *P. aeruginosa*, MBL, epidemiology, prevalence, Gram-negative, national survey, and resistance. Countries were grouped by continent in order to show international differences in CRPA prevalence related to geographi-




Figure 1. Geographical distribution of carbapenem-resistant *Pseudomonas aeruginosa*. Most isolates were collected from 2009 to 2011 with the following exceptions: Chile (2005), Kenya (2006 to 2007), and South Africa (2006). The white colored areas indicate that there was no available published data for that region.

Table 2. Imipenemase-type metallo- β -lactamases found in *Pseudomonas aeruginosa*

IMP variant	Frequently identified sequence types	Country of isolation	Reported gene location	Reference(s) or GenBank accession No.
IMP-1	175, 186, 235, 244, 277, 308, 360, 357, 593, 645, 964, 1,015, 1,070, 1,162	Japan	CII	[38, 87]
		South Korea	CII	[63]
		Brazil	Unknown	[23]
		China	Unknown	[88]
		Turkey	CII	[89]
		Singapore	Unknown	[90]
		Thailand	CII	[91]
		Iran	CII	[92]
IMP-2	NR	Japan	CII	[93]
IMP-4	NR	Malaysia	Unknown	[94]
		Australia	CII	[95]
		China	CII	[96]
IMP-5	NR	Portugal	CII	[97]
IMP-6	235, 244, 591, 744, 745, 1,015, 1,162	South Korea	CII	[98]
		China	Unknown	[99]
IMP-7	235, 357, 744, 745	Canada	CII	[100]
		Malaysia	Unknown	[101]
		Slovakia	Unknown	[102]
		Japan	CII	[103]
		Singapore	Unknown	[90]
		Czech Republic	CII	[104]
Denmark	Unknown	[105]		
IMP-8	308	Germany	CII	[43]
IMP-9	NR	China	CII	[106]
		Malaysia	CII	[107]
IMP-10	NR	Japan	CII	[108]
		China	CII	[109]
IMP-11	NR	Japan	Unknown	AB074437
IMP-13	111, 308, 621	Austria	CII	[110]
		Italy	CII	[111]
		France	CII	[112]
		Belgium	CII	[113]
IMP-14	260	Thailand	CII	[114]
IMP-15	606, 654, 1,446	Mexico	CII	[115]
		Spain	CII	[116]
		Germany	Unknown	[76]
IMP-16	NR	Brazil	CII	[117]
IMP-18	NR	USA	Unknown	[118]
		Mexico	CII	[119]
		Puerto Rico	CII	[120]
IMP-19	235	Japan	Unknown	AB184876
		Italy	CII	[121]
IMP-20	NR	Japan	CII	AB196988
IMP-21	NR	Japan	CII	AB204557

Table 2. Continued

IMP variant	Frequently identified sequence types	Country of isolation	Reported gene location	Reference(s) or GenBank accession No.
IMP-22	175, 620	Austria	CII	[110]
		Italy	CII	[122]
IMP-25		China	CII	EU352796
IMP-26	235, 654	Malaysia	CII	[123]
		Singapore	Unknown	[31]
IMP-29	235	France	CII	[124]
IMP-30	NR	Russia	Unknown	[125]
IMP-31	235	Germany	Unknown	[126]
IMP-33	NR	Italy	CII	[127]
IMP-35	622	Germany	CII	[128]
IMP-37	111, 308, 621	France	Unknown	JX131372
IMP-40	NR	Japan	Unknown	AB753457
IMP-41	NR	Japan	Unknown	AB753458
IMP-43	235, 357	Japan	CII	[129]
IMP-44	357	Japan	CII	[129]
IMP-45	308	China	CII	[130]
IMP-48	NR	USA	Unknown	KM087857

IMP, imipenemase; CII, Class 1 integron; NR, not reported.

cal distance. We found published reports from a total of 50 countries regarding country of isolation and collection period of clinical isolates, as well as the ratio of CRPA to all *P. aeruginosa* (Table 1).

In most countries, the reported CRPA ratio ranged from 10 to 50%. The carbapenem resistance rates in Canada (carbapenem 3.3%) and the Dominican Republic (imipenem and meropenem, both 8%) were the lowest of all countries, with ratios lower than 10%. On the other hand, ratios in Brazil, Peru, Costa Rica, Russia, Greece, Poland, Iran, and Saudi Arabia were higher than 50% in all drugs of the carbapenem class (imipenem, meropenem, doripenem, ertapenem) ranging from 50% to 75.3% (Fig. 1). As shown in Figure 1, Russia, Southwest Asia, and South America were the predominant areas with antimicrobial resistance rates high enough to cause concern for public health to microbiologists and infection specialists.

The geographical distribution and ratio of CRPA differed from country to country; many CRPA strains have been identified and their prevalence is increasing gradually. The worldwide emergence of carbapenem-resistant strains with similar mobile genetic elements indicates the dissemination of genes encoding carbapenemases through horizontal gene transfer [26]. The increase in CRPA ratio is known to be driven by both

carbapenem use and the application of medical devices, which prompt the selection of resistant organisms [27]. Both factors are related to patient characteristics and clinical practice policies and/or antibiotic prescription patterns of health care facilities in each country.

Resistance mechanisms to carbapenem can be categorized into (1) deficiency of the outer membrane porin OprD, (2) bacterial production of carbapenemases, or (3) overexpression of efflux pump [28-32]. Carbapenem resistance in *P. aeruginosa* is most often associated with OprD deficiency and less frequently with the release of carbapenemase by the pathogen [33-35].

Carbapenemases from each β -lactamase Ambler class have been identified in *P. aeruginosa*. Of these, Ambler class B β -lactamases are the most clinically significant carbapenemases and are called metallo- β -lactamase (MBL) because a metal ion, such as Zn^{2+} , is essential for their activity, which can be inhibited by metal ion chelators.

Types of metallo- β -lactamases in *P. aeruginosa*

MBLs efficiently hydrolyze carbapenems and other β -lactams (except monobactams) and are not inhibited by the clinically available β -lactamase inhibitors including clavulanic

Table 3. Verona integron-encoded metallo- β -lactamases found in *Pseudomonas aeruginosa*

VIM type MBL	Frequently identified sequence type	Country of isolation	Reported gene location	Reference(s) or GenBank accession No.
VIM-1	17, 111, 227, 228, 235	Italy	CII	[39]
		France	CII	[131]
		Greece	CII	[132]
		Germany	Unknown	[76]
		Italy	CII	[121]
VIM-2	17, 111, 155, 175, 179, 229, 233, 235, 244, 309, 364, 639, 640, 654, 773, 811, 973, 1,020, 1,074, 1,699, 1,700	Tunisia	CII	[133]
		Thailand	Unknown	[114]
		Austria	CII	[110]
		Mexico	CII	[115]
		India	Unknown	[134]
		Kenya	Unknown	[80]
		Hungary	CII	[135]
		Malaysia	CII	[136]
		South Korea	CII	[19]
		Japan	CII	[137]
		France	CII	[138]
		Greece	CII	[139]
		Italy	CII	[140]
		Portugal	CII	[141]
		Spain	Unknown	[142]
		Croatia	CII	[143]
		Poland	CII	[144]
		Chile	CII	[44]
		Venezuela	CII	[44]
		Argentina	Unknown	[44]
USA	CII	[44]		
Belgium	Unknown	[76]		
Germany	Unknown	[76]		
Turkey	Unknown	[76]		
Egypt	CII	[145]		
VIM-3	298	Taiwan	Unknown	[146]
VIM-4	111, 229, 230, 235, 313	Greece	CII	[44]
		Sweden	Unknown	[44]
		Poland	CII	[44]
		Hungary	CII	[135, 147]
		France	Unknown	[76]
VIM-5	85, 534	India	Unknown	[134]
		Turkey	CII	[44]
VIM-6	85, 746	India	CII	[134]
		Indonesia	CII	[148]
		South Korea	CII	[148]
		Philippines	CII	[148]
VIM-7	NR	USA	CII	[149]
VIM-8	NR	Columbia	Unknown	[150]

Table 3. Continued

VIM type MBL	Frequently identified sequence type	Country of isolation	Reported gene location	Reference(s) or GenBank accession No.
VIM-9	NR	UK	Unknown	AY524988
VIM-10	NR	UK	Unknown	[151]
VIM-11	NR	India	C1I	[134]
		Argentina	Unknown	[152]
		Italy	Unknown	AY635904
		Malaysia	C1I	[136]
VIM-13	235	Spain	C1I	[153]
VIM-14	260	Spain	Unknown	EF055455
		Italy	C1I	[154]
VIM-15	NR	Bulgaria	C1I	[155]
VIM-16	NR	Germany	C1I	[155]
VIM-17	NR	Greece	C1I	[156]
VIM-18	NR	India	C1I	[134]
VIM-20	NR	Spain	Unknown	[157]
VIM-28	NR	Egypt	C1I	[158]
VIM-30	NR	France	C1I	JN129451
VIM-36	111	Belgium	Unknown	[76]
VIM-37	NR	Poland	Unknown	[76]
VIM-38	NR	Turkey	C1I	[159]
VIM-43	NR	USA	Unknown	KP096412

VIM, Verona-integron-encoded metallo- β -lactamase; MBL, metallo- β -lactamase; C1I, Class 1 integron; NR, not reported.

acid or tazobactam. Except for the SPM-type enzymes, most MBL genes reside within various compositions of integron gene cassettes that are encoded on genes linked to mobile elements, which is a condition that facilitates their spread among different bacterial species and genera through horizontal gene transfer [36, 37]. The most notable of the acquired MLBs, the IMP- and VIM-type enzymes, were first detected in the early 1990s [38, 39]. Thereafter, many additional types of acquired MBLs have been reported, including the SPM-, GIM-, SIM-, KHM-, NDM-, AIM-, DIM-, SMB-, TMB-, and FIM-type enzymes [40, 41]. Since the discovery of IMP-1, which was the first MBL identified in *P. aeruginosa*, IMP-, VIM-, SPM-, GIM-, NDM- and FIM-type variants in *P. aeruginosa* have been reported steadily.

Imipenemase (IMP)

In 1988, transferable IMP-1 was first isolated from *P. aeruginosa* in Japan [38] and was found in a class 1 integron located on a conjugational plasmid. Thereafter, it was identified in many other species suggesting horizontal gene transfer of

*bla*_{IMP-1} between unrelated Gram-negative species, and also showed predominance of specific IMP type-producing isolates demonstrating clonal expansion [15]. Currently 33 of the 51 known IMP variants have been identified from *P. aeruginosa*, including the recent detection of IMP-8-producing strains in Germany [42, 43] (Table 2). IMP-like enzymes are divided into several subgroups, and the percentage amino acid identity within these subgroups ranges from 90% to 99% showing very similar hydrolytic activities among them [44].

Verona integron-encoded metallo- β -lactamase (VIM)

VIM enzymes share the same hydrolytic spectrum the IMP-type enzymes, with less than 40% amino acid identity [45]. VIM-1 was identified first in *P. aeruginosa* in 1999, and after that, has also been reported in other Gram-negative species from several countries [39]. Currently, VIM-2 is the most widespread MBL in *P. aeruginosa* and has been the source of multiple outbreaks [44]. Twenty-four of the 46 VIM variants, including VIM-43 found in the USA (GenBank accession

Table 4. Other metallo- β -lactamases found in *Pseudomonas aeruginosa*

MBL enzymes	Frequently identified sequence type	Country of isolation	Reported gene location	Reference(s) or GenBank accession No.
NDM-1	235	Serbia	Chromosome	[20]
		France	Chromosome	[54, 55]
		India	Plasmid	[56]
		Italy	Chromosome	[57]
		Egypt	Unknown	[58]
		Slovakia	Unknown	[59]
SPM-1	NR	Brazil	ISCR4	[160]
		Switzerland	ISCR4	[48]
GIM-1	NR	Germany	Class 1 Integron, Plasmid	[51, 52]
FIM-1	235	Italy	Chromosome	[60]

MBL, metallo- β -lactamase; NDM, New Delhi metallo- β -lactamase; SPM, Sao Paulo metallo- β -lactamase; NR, not reported; ISCR4, insertion sequence common region 4; GIM, Germany imipenemase; FIM, Florence imipenemase.

number KP096412), have been identified in *P. aeruginosa* (Table 3).

Sao Paulo metallo- β -lactamase (SPM)

SPM-1 was first isolated in Brazil in 1997 from a *P. aeruginosa* clinical isolate that was resistant to all available antibiotics except colistin [46] (Table 4). SPM is quite different from VIM and IMP, presenting the highest amino acid identity to IMP-1 (35.5%), and represents a new subfamily of MBLs. Dissemination of MDR *P. aeruginosa* producing SPM-1 was demonstrated in distinct regions of Brazil; however, these strains have not yet spread to other countries, with only one exception of a single isolate identified in a Swiss patient who had previously been hospitalized in Brazil [47, 48]. The *bla*_{SPM-1} gene has been reported in *Pseudomonas* and *Acinetobacter* spp. isolated from various hospitals in Brazil, and its product is a major contributor to the high level carbapenem resistance observed in South America. Currently, the ratio of carbapenem resistance in South America is among the highest in the world [49]. The *bla*_{SPM-1} gene is either chromosomal or plasmid-encoded. In addition, it is associated with the insertion sequence common region 4 (ISCR4) at the origin of its acquisition and expression and is likely transposed through a rolling-circle replication mechanism [50].

Germany imipenemase (GIM)

In 2002, GIM-1 was identified in *P. aeruginosa* isolates from Germany (Table 4). Molecular analysis revealed that the ami-

no acid sequence identity of GIM-1 with other clinically significant MBL genes, including IMP and VIM variants, was less than 45%, indicating that GIM-1 is a new phylogenetic subclass of MBLs. Initially, this enzyme was not predicted to be mobile because the 22-kb plasmid carrying In77 is nonconjugative and has a restricted host range [51]; however, GIM-1 has also been found in *Enterobacter cloacae*, *Pseudomonas putida*, *Serratia marcescens*, *Escherichia coli*, *Klebsiella oxytoca*, and *Citrobacter freundii* [52]. Molecular analysis of class 1 integron arrays showed that most *bla*_{GIM-1} gene cassettes shared identical elements (*aacA4*, *aadA1*, and *bla*_{OXA-2}), which demonstrates horizontal gene transfer of a large block of genetic information [52]. To date, there have been no reports of GIM-1-producing strains outside of Germany.

New Delhi metallo- β -lactamase (NDM)

NDM-1 was first isolated in *Klebsiella pneumoniae* and *Escherichia coli* recovered from a patient who was previously admitted to a hospital in New Delhi, India, in 2009 [53]. Since then, additional six NDM variants (NDM-2 to NDM-7) have been identified in *P. aeruginosa*, *Acinetobacter baumannii*, and *E. coli*. NDM-1-producing *P. aeruginosa* strains were first reported in 2011, with two isolates recovered from Serbia [20] (Table 4). In 2012, NDM-1-producing *P. aeruginosa* sequence type 235 (ST235) strain was isolated in France from a patient previously hospitalized in Serbia [54, 55]. Since then, NDM-1-positive *P. aeruginosa* isolates have been recovered throughout the world including India, Italy, Egypt, and Slovakia [56-59].

Florence imipenemase (FIM-1)

In 2012, a novel FIM-1 MBL was isolated from a MDR *P. aeruginosa* in Florence (Italy) that showed highest similarity (40% amino acid identity) with NDM-type enzymes [60] (Table 4). This isolate belonged to the ST235 epidemic clonal lineage. Analysis of the kinetic parameters showed that FIM-1 has a broad substrate specificity, especially with penicillins and carbapenems. The *bla*_{FIM-1} gene was chromosomally located and was associated with ISCR19-like elements that were likely involved in its capture and mobilization; its origin remains unknown [60].

Metallo- β -lactamase-producing *P. aeruginosa* in Korea

VIM-2 was first described in *P. aeruginosa* isolated from the blood culture of a woman treated with imipenem in Marseilles, France, in 1996 [62]. The first reported MBL in Korea was a VIM-2-producing *P. aeruginosa* isolated in 2002 [19]. Since then, many MBL enzymes including VIM-2 have been detected in *P. aeruginosa*, *Acinetobacter* spp., and *Enterobacteriaceae* isolates. The prevalence of dominant MBL types has changed with time. In 2003, more than 10% of imipenem-resistant *P. aeruginosa* produced VIM-2 type MBL, but the ratio of VIM-2 carriage decreased to 7.7% according to a study in 2005, which was followed by IMP-1 at 2.4% and IMP-6 at 0.7% [63-65]. In 2011, the ratio of imipenem-resistant *P. aeruginosa* was 22% among 15,032 clinical isolates in Korea, and IMP-6 became the dominant MBL enzyme in Korea, representing 7.8% of all *P. aeruginosa* clinical isolates, followed by VIM-2 at 0.3% [66]. This trend in MPPA was also found in 2015; although the prevalence of MPPA in *P. aeruginosa* clinical isolates slightly decreased from 8.0% (31/386) to 6.4% (21/329), IMP-6 was still the most frequently detected MBL type in *P. aeruginosa* in Korea, followed by VIM-2 at 1.2% (4/329), which is different from the worldwide prevalence of VIM-2 [66-68]. IMP-6 was first identified in Japan in 1996 in plasmid pKU501 from *Serratia marcescens* KU383. It showed very similar amino acid identity with IMP-1 MBL, differing by only one Ser196Gly amino acid substitution, resulting in augmented hydrolytic activity for meropenem [69].

Molecular analysis demonstrated that ST235 is the most dominant MPPA in Korea [67]. Association of ST235-like strains with MBL genes has been reported in several European countries, with VIM-1-producers in Italy; VIM-4-producers in Greece, Sweden, Hungary and Belgium; VIM-13-producers

in Spain; and IMP-29-producers in France [42]. This clone might therefore possess some specific traits enhancing its clonal dissemination. The combination of prevalent sequence types and specific MBL enzymes might suggest the keys to understand the proliferation of resistant strains and mechanisms of gene transfer. Given that MPPA ST235 was the only strain detected in Korea five years ago, it is also worthy to note that MPPA ST309 and ST463 have emerged along with the prevalent MPPA ST235 strain because this clonal diversity might be a sign of alarm for additional dissemination of MPPA in Korea.

Conclusion

The emergence and dissemination of MPPA is a global concern threatening not only immunocompromised patients, but also healthy members of the community. MPPA is an important bacteria due to the antimicrobial resistance characteristics as well as its pathogenicity. It contains multiple antimicrobial resistance genes and has the potential to transfer these to other strains, which is a major clinical problem because of limited treatment options for patients infected with MPPA. There are many obstacles to overcome regarding bacterial resistance. These can be broadly categorized into issues of emergence, spread, and clonal expansion with diversity. These factors are related to each other and are very difficult to control. Several factors are already well known to cause the proliferation of resistant strains, which include natural genetic diversification caused by mutation, horizontal gene transfer among other species, an increase of international travel and patient transfer between countries raising the possibility for further dissemination of resistant strains, and greater antibiotic selective pressure especially in immunocompromised patients who received aggressive and invasive treatment. Further studies on epidemiology, antimicrobial resistance mechanisms, proper antibiotic stewardship, and rapid diagnostic methods for detection of MPPA are recommended in order to develop strategies that contain the dissemination and limit the transmission of MPPA.

Conflicts of Interest

No conflicts of interest.

Acknowledgement

This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120843).

ORCID

Duck Jin Hong	http://orcid.org/0000-0003-1838-4041
Il Kwon Bae	http://orcid.org/0000-0003-1633-3240
In-Ho Jang	http://orcid.org/0000-0002-2881-5389
Seok Hoon Jeong	http://orcid.org/0000-0001-9290-897X
Hyun-Kyung Kang	http://orcid.org/0000-0001-5550-241X
Kyungwon Lee	http://orcid.org/0000-0003-3788-2134

References

- Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. *Science* 2009;325:1089-93.
- McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med* 2005;353:2433-41.
- Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. *Nat Med* 2007;13:295-8.
- Munoz-Price LS, Weinstein RA. Acinetobacter infection. *N Engl J Med* 2008;358:1271-81.
- Oliver A, Canton R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable *Pseudomonas aeruginosa* in cystic fibrosis lung infection. *Science* 2000;288:1251-4.
- Lautenbach E, Synnestevedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Imipenem resistance in *Pseudomonas aeruginosa*: emergence, epidemiology, and impact on clinical and economic outcomes. *Infect Control Hosp Epidemiol* 2010;31:47-53.
- Garner MJ, Carson C, Lingohr EJ, Fazil A, Edge VL, Trumble Waddell J. An assessment of antimicrobial resistant disease threats in Canada. *PLoS One* 2015;10:e0125155.
- Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, Leblebicioglu H, Fisher D, Álvarez-Moreno C, Khader IA, Del Rocío González Martínez M, Cuellar LE, Navoa-Ng JA, Abouqal R, Guancho Garcell H, Mitrev Z, Pirez García MC, Hamdi A, Dueñas L, Cancel E, Gurskis V, Rasslan O, Ahmed A, Kanj SS, Ugalde OC, Mapp T, Raka L, Yuet Meng C, Thu le TA, Ghazal S, Gikas A, Narváez LP, Mejía N, Hadjieva N, Gamar Elanbya MO, Guzmán Siritt ME, Jayatilleke K; INICC members. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. *Am J Infect Control* 2012;40:396-407.
- Schneider H, Geginat G, Hogardt M, Kramer A, Dürken M, Schrotten H, Tenenbaum T. *Pseudomonas aeruginosa* outbreak in a pediatric oncology care unit caused by an errant water jet into contaminated siphons. *Pediatr Infect Dis J* 2012;31:648-50.
- Nagao M, Iinuma Y, Igawa J, Saito T, Yamashita K, Kondo T, Matsushima A, Takakura S, Takaori-Kondo A, Ichiyama S. Control of an outbreak of carbapenem-resistant *Pseudomonas aeruginosa* in a haemato-oncology unit. *J Hosp Infect* 2011;79:49-53.
- Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, Cellini M, Frenos S, Milano GM, Cappelli B, Licciardello M, Beretta C, Aricò M, Castagnola E; Infection Study Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Multidrug resistant *Pseudomonas aeruginosa* infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. *Haematologica* 2010;95:1612-5.
- Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. Pharmacokinetic/pharmacodynamic investigation of colistin against *Pseudomonas aeruginosa* using an *in vitro* model. *Antimicrob Agents Chemother* 2010;54:3783-9.
- Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N. Spread of colistin resistant non-mucoid *Pseudomonas aeruginosa* among chronically infected Danish cystic fibrosis patients. *J Cyst Fibros* 2008;7:391-7.
- Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multi-drug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: resistance mechanisms and implications for therapy. *Expert Rev Anti Infect Ther* 2010;8:71-93.
- Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev* 2007;20:440-58, table of contents.
- Kitao T, Tada T, Tanaka M, Narahara K, Shimojima M, Shimada K, Miyoshi-Akiyama T, Kirikae T. Emergence of a novel multidrug-resistant *Pseudomonas aeruginosa* strain producing IMP-type metallo-beta-lactamases and AAC(6')-Iae in Japan. *Int J Antimicrob Agents* 2012;39:518-21.
- Poirel L, Nordmann P, Lagrutta E, Cleary T, Munoz-Price LS. Emergence of KPC-producing *Pseudomonas aeruginosa* in the United States. *Antimicrob Agents Chemother* 2010;54:3072.
- Wang C, Cai P, Chang D, Mi Z. A *Pseudomonas aeruginosa* isolate producing the GES-5 extended-spectrum beta-lactamase. *J Antimicrob Chemother* 2006;57:1261-2.
- Lee K, Lim JB, Yum JH, Yong D, Chong Y, Kim JM, Livermore DM. *bla*_{VIM-2} cassette-containing novel integrons in metallo-beta-lactamase-producing *Pseudomonas aeruginosa* and *Pseudomonas putida* isolates disseminated in a

- Korean hospital. *Antimicrob Agents Chemother* 2002;46:1053-8.
20. Jovcic B, Lepsanovic Z, Suljagic V, Rackov G, Begovic J, Topisirovic L, Kojic M. Emergence of NDM-1 metallo-beta-lactamase in *Pseudomonas aeruginosa* clinical isolates from Serbia. *Antimicrob Agents Chemother* 2011;55:3929-31.
 21. Potron A, Poirel L, Nordmann P. Plasmid-mediated transfer of the *bla*_{NDM-1} gene in Gram-negative rods. *FEMS Microbiol Lett* 2011;324:111-6.
 22. Yezli S, Shibl AM, Memish ZA. The molecular basis of beta-lactamase production in Gram-negative bacteria from Saudi Arabia. *J Med Microbiol* 2015;64:127-36.
 23. Martins AF, Zavascki AP, Gaspareto PB, Barth AL. Dissemination of *Pseudomonas aeruginosa* producing SPM-1-like and IMP-1-like metallo-beta-lactamases in hospitals from southern Brazil. *Infection* 2007;35:457-60.
 24. Sevillano E, Gallego L, García-Lobo JM. First detection of the OXA-40 carbapenemase in *P. aeruginosa* isolates, located on a plasmid also found in *A. baumannii*. *Pathol Biol (Paris)* 2009;57:493-5.
 25. El Garch F, Bogaerts P, Bebrone C, Galleni M, Glupczynski Y. OXA-198, an acquired carbapenem-hydrolyzing class D beta-lactamase from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2011;55:4828-33.
 26. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among *Acinetobacter* spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. *J Antimicrob Chemother* 2009;63:55-9.
 27. Voor In 't Holt AF, Severin JA, Lesaffre EM, Vos MC. A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2014;58:2626-37.
 28. Yoneyama H, Nakae T. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1993;37:2385-90.
 29. Borgianni L, Prandi S, Salden L, Santella G, Hanson ND, Rossolini GM, Docquier JD. Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a *Pseudomonas aeruginosa* isolate from the United States. *Antimicrob Agents Chemother* 2011;55:140-5.
 30. Hocquet D, Plésiat P, Dehecq B, Mariotte P, Talon D, Bertrand X, ONERBA. Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by cef-tazidime-resistant *Pseudomonas aeruginosa* strains in France. *Antimicrob Agents Chemother* 2010;54:3512-5.
 31. Koh TH, Khoo CT, Tan TT, Arshad MA, Ang LP, Lau LJ, Hsu LY, Ooi EE. Multilocus sequence types of carbapenem-resistant *Pseudomonas aeruginosa* in Singapore carrying metallo-beta-lactamase genes, including the novel *bla*_{IMP-26} gene. *J Clin Microbiol* 2010;48:2563-4.
 32. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 2006;50:1633-41.
 33. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev* 2001;14:933-51, table of contents.
 34. Jacoby GA, Munoz-Price LS. The new beta-lactamases. *N Engl J Med* 2005;352:380-91.
 35. Walsh TR. Clinically significant carbapenemases: an update. *Curr Opin Infect Dis* 2008;21:367-71.
 36. Partridge SR, Tsafnat G, Coiera E, Iredell JR. Gene cassettes and cassette arrays in mobile resistance integrons. *FEMS Microbiol Rev* 2009;33:757-84.
 37. Edelstein MV, Skleenova EN, Shevchenko OV, D'Souza JW, Tapalski DV, Azizov IS, Sukhorukova MV, Pavlukov RA, Kozlov RS, Toleman MA, Walsh TR. Spread of extensively resistant VIM-2-positive ST235 *Pseudomonas aeruginosa* in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. *Lancet Infect Dis* 2013;13:867-76.
 38. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1991;35:147-51.
 39. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Rossolini GM. Cloning and characterization of *bla*_{VIM}, a new integron-borne metallo-beta-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother* 1999;43:1584-90.
 40. Wachino J, Yoshida H, Yamane K, Suzuki S, Matsui M, Yamagishi T, Tsutsui A, Konda T, Shibayama K, Arakawa Y. SMB-1, a novel subclass B3 metallo-beta-lactamase, associated with ISCR1 and a class 1 integron, from a carbapenem-resistant *Serratia marcescens* clinical isolate. *Antimicrob Agents Chemother* 2011;55:5143-9.
 41. El Salabi A, Borra PS, Toleman MA, Samuelsen Ø, Walsh TR. Genetic and biochemical characterization of a novel metallo-beta-lactamase, TMB-1, from an *Achromobacter xylosoxidans* strain isolated in Tripoli, Libya. *Antimicrob*

- Agents Chemother 2012;56:2241-5.
42. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: Mechanisms and epidemiology. Int J Antimicrob Agents 2015;45:568-85.
 43. Willmann M, Bezdán D, Zapata L, Susak H, Vogel W, Schröppel K, Liese J, Weidenmaier C, Autenrieth IB, Ossowski S, Peter S. Analysis of a long-term outbreak of XDR *Pseudomonas aeruginosa*: a molecular epidemiological study. J Antimicrob Chemother 2015;70:1322-30.
 44. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306-25.
 45. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002;8:321-31.
 46. Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN, Walsh TR. Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J Antimicrob Chemother 2002;50:673-9.
 47. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant *Pseudomonas aeruginosa* producing SPM metallo-beta-lactamase. J Antimicrob Chemother 2003;52:699-702.
 48. Salabi AE, Toleman MA, Weeks J, Bruderer T, Frei R, Walsh TR. First report of the metallo-beta-lactamase SPM-1 in Europe. Antimicrob Agents Chemother 2010;54:582.
 49. Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR. Emerging epidemic of metallo-beta-lactamase-mediated resistances. Diagn Microbiol Infect Dis 2005;51:77-84.
 50. Toleman MA, Bennett PM, Walsh TR. ISCR elements: novel gene-capturing systems of the 21st century? Microbiol Mol Biol Rev 2006;70:296-316.
 51. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a beta-lactamase gene, *bla*_{GIM-1}, encoding a new subclass of metallo-beta-lactamase. Antimicrob Agents Chemother 2004;48:4654-61.
 52. Wendel AF, Brodner AH, Wydra S, Ressina S, Henrich B, Pfeiffer K, Toleman MA, Mackenzie CR. Genetic characterization and emergence of the metallo-beta-lactamase GIM-1 in *Pseudomonas* spp. and *Enterobacteriaceae* during a long-term outbreak. Antimicrob Agents Chemother. 2013;57:5162-5.
 53. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-beta-lactamase gene, *bla*_{NDM-1}, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046-54.
 54. Flateau C, Janvier F, Delacour H, Males S, Ficko C, Andriamanantena D, Jeannot K, Merens A, Rapp C. Recurrent pyelonephritis due to NDM-1 metallo-beta-lactamase producing *Pseudomonas aeruginosa* in a patient returning from Serbia, France, 2012. Euro Surveill 2012;17:pii:20311.
 55. Janvier F, Jeannot K, Tessé S, Robert-Nicoud M, Delacour H, Rapp C, Mérens A. Molecular characterization of *bla*_{NDM-1} in a sequence type 235 *Pseudomonas aeruginosa* isolate from France. Antimicrob Agents Chemother 2013;57:3408-11.
 56. Khajuria A, Praharaj AK, Kumar M, Grover N. Emergence of NDM - 1 in the clinical isolates of *Pseudomonas aeruginosa* in India. J Clin Diagn Res 2013;7:1328-31.
 57. Carattoli A, Fortini D, Galetti R, Garcia-Fernandez A, Nardi G, Orazi D, Capone A, Majolino I, Proia A, Mariani B, Parisi G, Morrone A, Petrosillo N. Isolation of NDM-1-producing *Pseudomonas aeruginosa* sequence type ST235 from a stem cell transplant patient in Italy, May 2013. Euro Surveill 2013;18:pii:20633.
 58. Zafer MM, Amin M, El Mahallawy H, Ashour MS, Al Agamy M. First report of NDM-1-producing *Pseudomonas aeruginosa* in Egypt. Int J Infect Dis 2014;29:80-1.
 59. Kulkova N, Babalova M, Sokolova J, Krcmery V. First report of New Delhi metallo-beta-lactamase-1-producing strains in Slovakia. Microb Drug Resist 2015;21:117-20.
 60. Pollini S, Maradei S, Pecile P, Olivo G, Luzzaro F, Docquier JD, Rossolini GM. FIM-1, a new acquired metallo-beta-lactamase from a *Pseudomonas aeruginosa* clinical isolate from Italy. Antimicrob Agents Chemother 2013;57:410-6.
 61. Yong D, Shin HB, Kim YK, Cho J, Lee WG, Ha GY, Choi TY, Jeong SH, Lee K, Chong Y; KONSAR group. Increase in the prevalence of carbapenem-resistant *Acinetobacter* isolates and ampicillin-resistant non-typhoidal *Salmonella* species in Korea: A KONSAR study conducted in 2011. Infect Chemother 2014;46:84-93.
 62. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, Nordmann P. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a *Pseudomonas aeruginosa* clinical isolate in France. Antimicrob Agents Chemother 2000;44:891-7.
 63. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y; Korean Na-

- tionwide Surveillance of Antimicrobial Resistance Group. VIM- and IMP-type metallo-beta-lactamase-producing *Pseudomonas* spp. and *Acinetobacter* spp. in Korean hospitals. *Emerg Infect Dis* 2003;9:868-71.
64. Lee K, Ha GY, Shin BM, Kim JJ, Kang JO, Jang SJ, Yong D, Chong Y; Korean Nationwide Surveillance of Antimicrobial Resistance (KONSAR) group. Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing *Pseudomonas* spp. and increase of IMP-producing *Acinetobacter* spp. *Diagn Microbiol Infect Dis* 2004;50:51-8.
65. Lee K, Park AJ, Kim MY, Lee HJ, Cho JH, Kang JO, Yong D, Chong Y; KONSAR group. Metallo-beta-lactamase-producing *Pseudomonas* spp. in Korea: high prevalence of isolates with VIM-2 type and emergence of isolates with IMP-1 type. *Yonsei Med J* 2009;50:335-9.
66. Seok Y, Bae IK, Jeong SH, Kim SH, Lee H, Lee K. Dissemination of IMP-6 metallo-beta-lactamase-producing *Pseudomonas aeruginosa* sequence type 235 in Korea. *J Antimicrob Chemother* 2011;66:2791-6.
67. Hong JS, Kim JO, Lee H, Bae IK, Jeong SH, Lee K. Characteristics of metallo-beta-lactamase-producing *Pseudomonas aeruginosa* in Korea. *Infect Chemother* 2015;47:33-40.
68. Valenza G, Joseph B, Elias J, Claus H, Oesterlein A, Engelhardt K, Turnwald D, Frosch M, Abele-Horn M, Schoen C. First survey of metallo-beta-lactamases in clinical isolates of *Pseudomonas aeruginosa* in a German university hospital. *Antimicrob Agents Chemother* 2010;54:3493-7.
69. Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T, Inoue M. Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. *Antimicrob Agents Chemother* 2001;45:1343-8.
70. Xu J, Duan X, Wu H, Zhou Q. Surveillance and correlation of antimicrobial usage and resistance of *Pseudomonas aeruginosa*: a hospital population-based study. *PLoS One* 2013;8:e78604.
71. Kakeya H, Yamada K, Nakaie K, Takizawa E, Okada Y, Fujita A, Nakamura Y, Abe J, Hirose A, Kaneko Y, Hino M. A comparison of susceptibility of *Pseudomonas aeruginosa* clinical isolates to carbapenem antibiotics in our hospital. *Jpn J Antibiot* 2014;67:241-8.
72. Lee HS, Loh YX, Lee JJ, Liu CS, Chu C. Antimicrobial consumption and resistance in five Gram-negative bacterial species in a hospital from 2003 to 2011. *J Microbiol Immunol Infect* 2014 [Epub ahead of print].
73. Kiratisin P, Chongthaleong A, Tan TY, Lagamayo E, Roberts S, Garcia J, Davies T. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. *Int J Antimicrob Agents* 2012;39:311-6.
74. Mendes RE, Mendoza M, Banga Singh KK, Castanheira M, Bell JM, Turnidge JD, Lin SS, Jones RN. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). *Antimicrob Agents Chemother* 2013;57:5721-6.
75. Farajzadeh Sheikh A, Rostami S, Jolodar A, Tabatabaiefar MA, Khorvash F, Saki A, Shoja S, Sheikhi R. Detection of metallo-beta lactamases among carbapenem-resistant *Pseudomonas aeruginosa*. *Jundishapur J Microbiol* 2014;7:e12289.
76. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible *Pseudomonas aeruginosa* collected during 2009-11 in 14 European and Mediterranean countries. *J Antimicrob Chemother* 2014;69:1804-14.
77. Mansour SA, Eldaly O, Jiman-Fatani A, Mohamed ML, Ibrahim EM. Epidemiological characterization of *P. aeruginosa* isolates of intensive care units in Egypt and Saudi Arabia. *East Mediterr Health J* 2013;19:71-80.
78. Liakopoulos A, Mavroidi A, Katsifas EA, Theodosiou A, Karagouni AD, Miriagou V, Petinaki E. Carbapenemase-producing *Pseudomonas aeruginosa* from central Greece: molecular epidemiology and genetic analysis of class I integrons. *BMC Infect Dis* 2013;13:505.
79. Sefraoui I, Berrazeg M, Drissi M, Rolain JM. Molecular epidemiology of carbapenem-resistant *Pseudomonas aeruginosa* clinical strains isolated from western Algeria between 2009 and 2012. *Microb Drug Resist* 2014;20:156-61.
80. Pitout JD, Revathi G, Chow BL, Kabera B, Kariuki S, Nordmann P, Poirel L. Metallo-beta-lactamase-producing *Pseudomonas aeruginosa* isolated from a large tertiary centre in Kenya. *Clin Microbiol Infect* 2008;14:755-9.
81. Brink A, Moolman J, da Silva MC, Botha M; National Antibiotic Surveillance Forum. Antimicrobial susceptibility profile of selected bacteraemic pathogens from private institutions in South Africa. *S Afr Med J* 2007;97:273-9.
82. Mataseje LF, Bryce E, Roscoe D, Boyd DA, Embree J, Gravel D, Katz K, Kibsey P, Kuhn M, Mouchili A, Simor A, Taylor G, Thomas E, Turgeon N, Mulvey MR; Canadian Nosocomial Infection Surveillance Program. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). *J Antimicrob Chemother* 2012;67:1359-67.

83. Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutiérrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L, Rodriguez-Noriega E. Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005-2010. *BMC Res Notes* 2012;5:277.
84. Perez F, Hujer AM, Marshall SH, Ray AJ, Rather PN, Suwantarat N, Dumford D 3rd, O'Shea P, Domitrovic TN, Salata RA, Chavda KD, Chen L, Kreiswirth BN, Vila AJ, Haussler S, Jacobs MR, Bonomo RA. Extensively drug-resistant *Pseudomonas aeruginosa* isolates containing *bla*_{VIM-2} and elements of *Salmonella* genomic island 2: a new genetic resistance determinant in Northeast Ohio. *Antimicrob Agents Chemother* 2014;58:5929-35.
85. Toval F, Guzmán-Marte A, Madriz V, Somogyi T, Rodríguez C, García F. Predominance of carbapenem-resistant *Pseudomonas aeruginosa* isolates carrying *bla*_{IMP} and *bla*_{VIM} metallo-beta-lactamases in a major hospital in Costa Rica. *J Med Microbiol* 2015;64:37-43.
86. Labarca JA, Salles MJ, Seas C, Guzmán-Blanco M. Carbapenem resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in the nosocomial setting in Latin America. *Crit Rev Microbiol* 2014 [Epub ahead of print].
87. Mano Y, Saga T, Ishii Y, Yoshizumi A, Bonomo RA, Yamaguchi K, Tateda K. Molecular analysis of the integrons of metallo-beta-lactamase-producing *Pseudomonas aeruginosa* isolates collected by nationwide surveillance programs across Japan. *BMC Microbiol* 2015;15:41.
88. Qu TT, Zhang JL, Wang J, Tao J, Yu YS, Chen YG, Zhou JY, Li LJ. Evaluation of phenotypic tests for detection of metallo-beta-lactamase-producing *Pseudomonas aeruginosa* strains in China. *J Clin Microbiol* 2009;47:1136-42.
89. Ozgumus OB, Caylan R, Tosun I, Sandalli C, Aydin K, Koksali I. Molecular epidemiology of clinical *Pseudomonas aeruginosa* isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey. *Microb Drug Resist* 2007;13:191-8.
90. Koh TH, Wang GC, Sng LH. Clonal spread of IMP-1-producing *Pseudomonas aeruginosa* in two hospitals in Singapore. *J Clin Microbiol* 2004;42:5378-80.
91. Boonkerd N, Pibalpakdi P, Tiloklurs M, Niumsup PR. Class 1 integron containing metallo beta-lactamase gene *bla*_{IMP-1} in carbapenem-resistant *Pseudomonas aeruginosa* in Thailand. *J Infect Chemother* 2009;15:257-61.
92. Fallah F, Borhan RS, Hashemi A. Detection of *bla*_{IMP} and *bla*_{VIM} metallo-beta-lactamases genes among *Pseudomonas aeruginosa* strains. *Int J Burns Trauma* 2013;3:122-4.
93. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, Kato H, Kai K, Arakawa Y. PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. *J Clin Microbiol* 2003;41:5407-13.
94. Bert F, Vanjak D, Leflon-Guibout V, Mrejen S, Delpierre S, Redondo A, Nicolas-Chanoine MH. IMP-4-producing *Pseudomonas aeruginosa* in a French patient repatriated from Malaysia: impact of early detection and control measures. *Clin Infect Dis* 2007;44:764-5.
95. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-beta-lactamase gene *bla*_{IMP-4} among gram-negative pathogens in a clinical setting in Australia. *Clin Infect Dis* 2005;41:1549-56.
96. Hawkey PM, Xiong J, Ye H, Li H, M'Zali FH. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in *Citrobacter youngae* from the People's Republic of China. *FEMS Microbiol Lett* 2001;194:53-7.
97. Brízio A, Conceição T, Pimentel M, Da Silva G, Duarte A. High-level expression of IMP-5 carbapenemase owing to point mutation in the -35 promoter region of class 1 integron among *Pseudomonas aeruginosa* clinical isolates. *Int J Antimicrob Agents* 2006;27:27-31.
98. Ryoo NH, Lee K, Lim JB, Lee YH, Bae IK, Jeong SH. Outbreak by meropenem-resistant *Pseudomonas aeruginosa* producing IMP-6 metallo-beta-lactamase in a Korean hospital. *Diagn Microbiol Infect Dis* 2009;63:115-7.
99. Chen Y, Sun M, Wang M, Lu Y, Yan Z. Dissemination of IMP-6-producing *Pseudomonas aeruginosa* ST244 in multiple cities in China. *Eur J Clin Microbiol Infect Dis* 2014;33:1181-7.
100. Gibb AP, Tribuddharat C, Moore RA, Louie TJ, Krulicki W, Livermore DM, Palepou MF, Woodford N. Nosocomial outbreak of carbapenem-resistant *Pseudomonas aeruginosa* with a new *bla*_{IMP} allele, *bla*_{IMP-7}. *Antimicrob Agents Chemother* 2002;46:255-8.
101. Ho SE, Subramaniam G, Palasubramaniam S, Navaratnam P. Carbapenem-resistant *Pseudomonas aeruginosa* in Malaysia producing IMP-7 beta-lactamase. *Antimicrob Agents Chemother* 2002;46:3286-7.
102. Ohlasova D, Kmet V, Niks M. First report of the carbapenem-resistant *Pseudomonas aeruginosa* producing IMP-7 metallo-beta-lactamase in Slovakia. *Int J Antimicrob Agents* 2007;30:370-1.
103. Kouda S, Kuwahara R, Ohara M, Shigeta M, Fujiwara T, Komatsuzawa H, Usui T, Sugai M. First isolation of

- bla*_{IMP-7} in *Pseudomonas aeruginosa* in Japan. J Infect Chemother 2007;13:276-7.
104. Hrabák J, Fridrichová M, Stolbová M, Bergerová T, Zemlickova H, Urbaskova P. First identification of metallo-beta-lactamase-producing *Pseudomonas aeruginosa* in the Czech Republic. Euro Surveill 2009;14:pii:19102.
 105. Hammerum AM, Jakobsen L, Hansen F, Stegger M, Sørensen LA, Andersen PS, Wang M. Characterisation of an IMP-7-producing ST357 *Pseudomonas aeruginosa* isolate detected in Denmark using whole genome sequencing. Int J Antimicrob Agents 2015;45:200-1.
 106. Xiong J, Hynes MF, Ye H, Chen H, Yang Y, M'Zali F, Hawkey PM. *bla*_{IMP-9} and its association with large plasmids carried by *Pseudomonas aeruginosa* isolates from the People's Republic of China. Antimicrob Agents Chemother 2006;50:355-8.
 107. Lim KT, Yasin RM, Yeo CC, Puthuchearu SD, Balan G, Maning N, Wahab ZA, Ismail N, Tan EA, Mustaffa A, Thong KL. Genetic fingerprinting and antimicrobial susceptibility profiles of *Pseudomonas aeruginosa* hospital isolates in Malaysia. J Microbiol Immunol Infect 2009;42:197-209.
 108. Iyobe S, Kusadokoro H, Takahashi A, Yomoda S, Okubo T, Nakamura A, O'Hara K. Detection of a variant metallo-beta-lactamase, IMP-10, from two unrelated strains of *Pseudomonas aeruginosa* and an alcaligenes xylosoxidans strain. Antimicrob Agents Chemother 2002;46:2014-6.
 109. Zhao WH, Chen G, Ito R, Hu ZQ. Relevance of resistance levels to carbapenems and integron-borne *bla*_{IMP-1}, *bla*_{IMP-7}, *bla*_{IMP-10} and *bla*_{VIM-2} in clinical isolates of *Pseudomonas aeruginosa*. J Med Microbiol 2009;58:1080-5.
 110. Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jelebean C. First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. Antimicrob Agents Chemother 2009;53:2221-2.
 111. Pagani L, Colinson C, Migliavacca R, Labonia M, Docquier JD, Nucleo E, Spalla M, Li Bergoli M, Rossolini GM. Nosocomial outbreak caused by multidrug-resistant *Pseudomonas aeruginosa* producing IMP-13 metallo-beta-lactamase. J Clin Microbiol 2005;43:3824-8.
 112. Fournier D, Jeannot K, Robert-Nicoud M, Muller E, Cholley P, van der Mee-Marquet N, Plésiat P. Spread of the *bla*_{IMP-13} gene in French *Pseudomonas aeruginosa* through sequence types ST621, ST308 and ST111. Int J Antimicrob Agents 2012;40:571-3.
 113. Naas T, Bogaerts P, Kostyanov T, Cuzon G, Huang TD, Ozsü S, Nordmann P, Glupczynski Y. Silent spread of IMP-13-producing *Pseudomonas aeruginosa* belonging to sequence type 621 in Belgium. J Antimicrob Chemother 2011;66:2178-9.
 114. Piyakul C, Tiyawisuttri R, Boonbumrung K. Emergence of metallo-beta-lactamase IMP-14 and VIM-2 in *Pseudomonas aeruginosa* clinical isolates from a tertiary-level hospital in Thailand. Epidemiol Infect 2012;140:539-41.
 115. Quinones-Falconi F¹, Galicia-Velasco M, Marchiaro P, Mussi MA, Ballerini V, Vila AJ, Viale AM, Bermejo-Morales K, Limansky AS. Emergence of *Pseudomonas aeruginosa* strains producing metallo-beta-lactamases of the IMP-15 and VIM-2 types in Mexico. Clin Microbiol Infect 2010;16:126-31.
 116. Gilarranz R, Juan C, Castillo-Vera J, Chamizo FJ, Artiles F, Álamo I, Oliver A. First detection in Europe of the metallo-beta-lactamase IMP-15 in clinical strains of *Pseudomonas putida* and *Pseudomonas aeruginosa*. Clin Microbiol Infect 2013;19:E424-7.
 117. Mendes RE, Toleman MA, Ribeiro J, Sader HS, Jones RN, Walsh TR. Integron carrying a novel metallo-beta-lactamase gene, *bla*_{IMP-16}, and a fused form of aminoglycoside-resistant gene *aac(6')-30/aac(6')-Ib'*: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2004;48:4693-702.
 118. Hanson ND, Hossain A, Buck L, Moland ES, Thomson KS. First occurrence of a *Pseudomonas aeruginosa* isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18. Antimicrob Agents Chemother 2006;50:2272-3.
 119. Garza-Ramos U, Tinoco P, Silva-Sanchez J, Morfin-Otero R, Rodriguez-Noriega E, Leon-Garnica G, Sader HS, Jones RN. Metallo-beta-lactamase IMP-18 is located in a class 1 integron (In96) in a clinical isolate of *Pseudomonas aeruginosa* from Mexico. Int J Antimicrob Agents 2008;31:78-80.
 120. Wolter DJ, Khalaf N, Robledo IE, Vázquez GJ, Santé MI, Aquino EE, Goering RV, Hanson ND. Surveillance of carbapenem-resistant *Pseudomonas aeruginosa* isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases. Antimicrob Agents Chemother 2009;53:1660-4.
 121. Pollini S, Antonelli A, Venturelli C, Maradei S, Veggetti A, Bracco S, Rumpianesi F, Luzzaro F, Rossolini GM. Acquisition of plasmid-borne *bla*_{IMP-19} gene by a VIM-1-positive *Pseudomonas aeruginosa* of the sequence type 235 epidemic lineage. J Antimicrob Chemother 2013;68:722-4.
 122. Pellegrini C, Mercuri PS, Celenza G, Galleni M, Segatore B, Sacchetti E, Volpe R, Amicosante G, Perilli M. Identifi-

- cation of *bla*_{IMP-22} in *Pseudomonas* spp. in urban wastewater and nosocomial environments: biochemical characterization of a new IMP metallo-enzyme variant and its genetic location. *J Antimicrob Chemother* 2009;63:901-8.
123. Kim MJ, Bae IK, Jeong SH, Kim SH, Song JH, Choi JY, Yoon SS, Thamlikitkul V, Hsueh PR, Yasin RM, Lalitha MK, Lee K. Dissemination of metallo-beta-lactamase-producing *Pseudomonas aeruginosa* of sequence type 235 in Asian countries. *J Antimicrob Chemother* 2013;68:2820-4.
 124. Jeannot K, Poirel L, Robert-Nicoud M, Cholley P, Nordmann P, Plésiat P. IMP-29, a novel IMP-type metallo-beta-lactamase in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2012;56:2187-90.
 125. Pegg KM, Liu EM, Lacuran AE, Oelschlaeger P. Biochemical characterization of IMP-30, a metallo-beta-lactamase with enhanced activity toward ceftazidime. *Antimicrob Agents Chemother* 2013;57:5122-6.
 126. Pfennigwerth N, Geis G, Gatermann SG, Kaase M. Description of IMP-31, a novel metallo-beta-lactamase found in an ST235 *Pseudomonas aeruginosa* strain in Western Germany. *J Antimicrob Chemother* 2015. [Epub ahead of print].
 127. Deshpande LM, Davies TA, Blandino G, Nicoletti G, Jones RN, Castanheira M. IMP-33, a New IMP variant detected in *Pseudomonas aeruginosa* from Sicily. *Antimicrob Agents Chemother* 2013;57:6401-3.
 128. Pournaras S, Köck R, Mossialos D, Mellmann A, Sakellaris V, Stathopoulos C, Friedrich AW, Tsakris A. Detection of a phylogenetically distinct IMP-type metallo-beta-lactamase, IMP-35, in a CC235 *Pseudomonas aeruginosa* from the Dutch-German border region (Euregio). *J Antimicrob Chemother* 2013;68:1271-6.
 129. Tada T, Miyoshi-Akiyama T, Shimada K, Shimojima M, Kirikae T. IMP-43 and IMP-44 metallo-beta-lactamases with increased carbapenemase activities in multidrug-resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2013;57:4427-32.
 130. Wang Y, Wang X, Schwarz S, Zhang R, Lei L, Liu X, Lin D, Shen J. IMP-45-producing multidrug-resistant *Pseudomonas aeruginosa* of canine origin. *J Antimicrob Chemother* 2014;69:2579-81.
 131. Corvec S, Poirel L, Decousser JW, Allouch PY, Drugeon H, Nordmann P. Emergence of carbapenem-hydrolysing metallo-beta-lactamase VIM-1 in *Pseudomonas aeruginosa* isolates in France. *Clin Microbiol Infect* 2006;12:941-2.
 132. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, Livermore DM. Outbreak of infections caused by *Pseudomonas aeruginosa* producing VIM-1 carbapenemase in Greece. *J Clin Microbiol* 2000;38:1290-2.
 133. Mansour W, Poirel L, Bettaieb D, Bouallegue O, Boujaafar N, Nordmann P. Metallo-beta-lactamase-producing *Pseudomonas aeruginosa* isolates in Tunisia. *Diagn Microbiol Infect Dis* 2009;64:458-61.
 134. Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. Carbapenem resistance among *Pseudomonas aeruginosa* strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). *Antimicrob Agents Chemother* 2009;53:1225-7.
 135. Libisch B, Watine J, Balogh B, Gacs M, Muzslay M, Szabó G, Füzi M. Molecular typing indicates an important role for two international clonal complexes in dissemination of VIM-producing *Pseudomonas aeruginosa* clinical isolates in Hungary. *Res Microbiol* 2008;159:162-8.
 136. Khosravi Y, Tee Tay S, Vadivelu J. Metallo-beta-lactamase-producing imipenem-resistant *Pseudomonas aeruginosa* clinical isolates in a university teaching hospital in Malaysia: detection of IMP-7 and first identification of IMP-4, VIM-2, and VIM-11. *Diagn Microbiol Infect Dis* 2010;67:294-6.
 137. Yatsuyanagi J, Saito S, Harata S, Suzuki N, Ito Y, Amano K, Enomoto K. Class 1 integron containing metallo-beta-lactamase gene *bla*_{VIM-2} in *Pseudomonas aeruginosa* clinical strains isolated in Japan. *Antimicrob Agents Chemother* 2004;48:626-8.
 138. Poirel L, Collet L, Nordmann P. Carbapenem-hydrolyzing metallo-beta-lactamase from a nosocomial isolate of *Pseudomonas aeruginosa* in France. *Emerg Infect Dis* 2000;6:84-5.
 139. Poole K. Overcoming multidrug resistance in gram-negative bacteria. *Curr Opin Investig Drugs* 2003;4:128-39.
 140. Pallecchi L, Riccio ML, Docquier JD, Fontana R, Rossolini GM. Molecular heterogeneity of *bla*_{VIM-2}-containing integrons from *Pseudomonas aeruginosa* plasmids encoding the VIM-2 metallo-beta-lactamase. *FEMS Microbiol Lett* 2001;195:145-50.
 141. Cardoso O, Leitão R, Figueiredo A, Sousa JC, Duarte A, Peixe LV. Metallo-beta-lactamase VIM-2 in clinical isolates of *Pseudomonas aeruginosa* from Portugal. *Microb Drug Resist* 2002;8:93-7.
 142. Prats G, Miro E, Mirelis B, Poirel L, Bellais S, Nordmann P. First isolation of a carbapenem-hydrolyzing beta-lactamase in *Pseudomonas aeruginosa* in Spain *Antimicrob*

- Agents Chemother 2002;46:932-3.
143. Sardelic S, Pallecchi L, Punda-Polic V, Rossolini GM. Carbapenem-resistant *Pseudomonas aeruginosa*-carrying VIM-2 metallo-beta-lactamase determinants, Croatia. Emerg Infect Dis 2003;9:1022-3.
144. Walsh TR, Toleman MA, Hryniewicz W, Bennett PM, Jones RN. Evolution of an integron carrying *bla*_{VIM-2} in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program. J Antimicrob Chemother 2003;52:116-9.
145. Zafer MM, Al-Agamy MH, El-Mahallawy HA, Amin MA, El Din Ashour S. Dissemination of VIM-2 producing *Pseudomonas aeruginosa* ST233 at tertiary care hospitals in Egypt. BMC Infect Dis 2015;15:122.
146. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, Wu JJ. Metallo-beta-lactamases in clinical *Pseudomonas* isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001;45:2224-8.
147. Libisch B, Gacs M, Csiszár K, Muzslay M, Rókus L, Füzi M. Isolation of an integron-borne *bla*_{VIM-4} type metallo-beta-lactamase gene from a carbapenem-resistant *Pseudomonas aeruginosa* clinical isolate in Hungary. Antimicrob Agents Chemother 2004;48:3576-8.
148. Castanheira M, Bell JM, Turnidge JD, Mendes RE, Jones RN. Dissemination and genetic context analysis of *bla*_{VIM-6} among *Pseudomonas aeruginosa* isolates in Asian-Pacific Nations. Clin Microbiol Infect 2010;16:186-9.
149. Toleman MA, Rolston K, Jones RN, Walsh TR. *bla*_{VIM-7}, an evolutionarily distinct metallo-beta-lactamase gene in a *Pseudomonas aeruginosa* isolate from the United States. Antimicrob Agents Chemother 2004;48:329-32.
150. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J, Velez JD, Castañeda CR, Recalde M, Livermore DM. Outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004;42:5094-101.
151. Woodford N, Zhang J, Kaufmann ME, Yarde S, Tomas Mdel M, Faris C, Vardhan MS, Dawson S, Cotterill SL, Livermore DM. Detection of *Pseudomonas aeruginosa* isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom. J Antimicrob Chemother 2008;62:1265-8.
152. Marchiaro P, Tomatis PE, Mussi MA, Pasteran F, Viale AM, Limansky AS, Vila AJ. Biochemical characterization of metallo-beta-lactamase VIM-11 from a *Pseudomonas aeruginosa* clinical strain. Antimicrob Agents Chemother 2008;52:2250-2.
153. Juan C, Beceiro A, Gutiérrez O, Albertí S, Garau M, Pérez JL, Bou G, Oliver A. Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a *Pseudomonas aeruginosa* clinical isolate in Spain. Antimicrob Agents Chemother 2008;52:3589-96.
154. Mazzariol A, Mammìna C, Koncan R, Di Gaetano V, Di Carlo P, Cipolla D, Corsello G, Cornaglia G. A novel VIM-type metallo-beta-lactamase (VIM-14) in a *Pseudomonas aeruginosa* clinical isolate from a neonatal intensive care unit. Clin Microbiol Infect 2011;17:722-4.
155. Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A. VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in *Pseudomonas aeruginosa* isolates from Bulgaria and Germany. Antimicrob Agents Chemother 2008;52:2977-9.
156. Siarkou VI, Vitti D, Protonotariou E, Ikonomidis A, Sofianou D. Molecular epidemiology of outbreak-related *Pseudomonas aeruginosa* strains carrying the novel variant *bla*_{VIM-17} metallo-beta-lactamase gene. Antimicrob Agents Chemother 2009;53:1325-30.
157. Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A. *Pseudomonas aeruginosa* carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011;66:2022-7.
158. El-Mahdy TS. Identification of a novel metallo-beta-lactamase VIM-28 located within unusual arrangement of class 1 integron structure in *Pseudomonas aeruginosa* isolates from Egypt. Jpn J Infect Dis 2014;67:382-4.
159. Iraz M, Duzgun AO, Cicek AC, Bonnin RA, Ceylan A, Saral A, Nordmann P, Sandalli C. Characterization of novel VIM carbapenemase, VIM-38, and first detection of GES-5 carbapenem-hydrolyzing beta-lactamases in *Pseudomonas aeruginosa* in Turkey. Diagn Microbiol Infect Dis 2014;78:292-4.
160. Poirel L, Magalhaes M, Lopes M, Nordmann P. Molecular analysis of metallo-beta-lactamase gene *bla*_{SPM-1}-surrounding sequences from disseminated *Pseudomonas aeruginosa* isolates in Recife, Brazil. Antimicrob Agents Chemother 2004;48:1406-9.